ORGO News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

OR

Mkt Cap

$128.7M

Volume

1.21M

Next Earnings

November 5th

Loading chart

OR

ORGOOrganogenesis Holdings Inc. Class A Common Stock

ORGO

Pay with—

Available Balance0.00

OR

Mkt Cap

$142.8M

Volume

1.21M

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Tissue Engineering Market to Grow at 12.95% CAGR Reaching USD 27.59 Billion by 2031, Driven by Advances in Regenerative Medicine and Biomaterials, Says Mordor IntelligenceThe global tissue engineering market is projected to grow from USD 15.01 billion in 2026 to USD 27.59 billion by 2031, driven by advancements in regenerative medicine, biomaterials, and stem cell research. Key growth drivers include increasing demand for regenerative therapies, innovations in 3D bioprinting, rising prevalence of chronic diseases, and expanding applications in orthopedics, skin regeneration, and dental restoration. North America leads the market while Asia-Pacific emerges as a high-growth region.GlobeNewswire Inc. · Apr 24, 2026

Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AMOrganogenesis Holdings Inc. announced that its randomized controlled trial of PuraPly®AM plus standard of care versus standard of care alone for non-healing diabetic foot ulcers achieved its primary endpoint, demonstrating statistically significant wound closure at 12 weeks (p<0.0477). The company plans to publish results in a peer-reviewed journal and believes the findings will support future coverage policies for the product.GlobeNewswire Inc. · Apr 6, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vizsla Silver Corp. - VZLAPomerantz LLP is investigating potential securities fraud claims on behalf of investors in Vizsla Silver Corp., following a security incident at its Mexico project site on January 29, 2026, where ten individuals were taken and operations were temporarily suspended. The incident triggered a 14.87% stock price decline. The firm is also investigating similar claims against Telesat Corporation and Organogenesis Holdings Inc.GlobeNewswire Inc. · Feb 3, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGOPomerantz LLP is investigating potential securities fraud claims against Organogenesis Holdings Inc. following the Centers for Medicare & Medicaid Services' withdrawal of Local Coverage Determinations for skin substitute grafts on December 26, 2025. The withdrawal exposes Organogenesis to increased competition from over 300 market participants. The company's stock price fell 10.14% to $5.28 per share on the news.GlobeNewswire Inc. · Dec 30, 2025

Global Wound Healing Devices Market Poised for Robust Growth at a CAGR of ~5% by 2032, Driven by Rising Chronic Wound Burden | DelveInsightThe global wound healing devices market is projected to grow from $29 billion in 2024 to $42 billion by 2032, driven by increasing chronic wounds, technological advancements, and an aging population.GlobeNewswire Inc. · Nov 20, 2025

Organogenesis Holdings Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ORGODJS Law Group is investigating Organogenesis Holdings for potential securities law violations after the company's second phase 3 trial of ReNu failed to achieve its primary endpoint, causing a 12.39% stock price drop.Benzinga · Oct 17, 2025

Why Is Organogenesis Stock Trading Lower Friday?Organogenesis Holdings reported results from its second Phase 3 trial for ReNu, a knee osteoarthritis treatment, which did not achieve statistical significance for its primary endpoint, causing the stock to drop 15.49%.Benzinga · Sep 26, 2025

12 Health Care Stocks Moving In Thursday's After-Market SessionMultiple healthcare stocks experienced significant price movements during Thursday's after-market trading session, with some companies seeing notable gains while others experienced declines.Benzinga · Sep 25, 2025

Organogenesis Provides Update on Second Phase 3 ReNu® StudyOrganogenesis reported mixed results for its ReNu knee osteoarthritis treatment in a second Phase 3 trial, showing numerical improvement in pain reduction but not meeting the primary statistical endpoint. The company plans to request a pre-BLA meeting with the FDA to discuss potential approval.GlobeNewswire Inc. · Sep 25, 2025

Organogenesis Provides Update on Second Phase 3 ReNu® StudyOrganogenesis reported results from its second Phase 3 trial for ReNu, a knee osteoarthritis treatment, which did not meet the primary endpoint but showed numerical improvement in pain reduction. The company plans to request a pre-BLA meeting with the FDA to discuss submission pathway.Benzinga · Sep 25, 2025

to start trading

OR

ORGOOrganogenesis Holdings Inc. Class A Common Stock

ORGO

Pay with—

Available Balance0.00

Your PositionYou don't own any ORGO yet.

Related Tickers

Earnings